US regulatory status: approved. Molecular target: DNA polymerase catalytic subunit.
- Target
- DNA polymerase catalytic subunit
- Mechanism
- Human herpesvirus 1 DNA polymerase inhibitor
biotech · Malignant Glioma · Prostate Cancer · CADL
Candel Therapeutics
Candel Therapeutics drug portfolio — 4 indexed compounds with therapeutic class and molecular targets from public FDA and regional approval metadata.
117 Kendrick Street, Suite 450, Needham, Massachusetts 02494, US HQ
1999 Founded
82 Employees
Public company Type
CADL · NYSE Ticker
Company details
- Status
- Public
- HQ
- 117 Kendrick Street, Suite 450, Needham, Massachusetts 02494, US
- Founded
- 1999
- Employees
- 82
- Programs
- 12
- Drugs
- 4
- Patents
- 0
Candel Therapeutics pipeline
Portfolio lens on 4 drugs and development assets — regulatory status, targets, and deep links to NovaPharmaNews drug profiles.
Candel Therapeutics drug portfolio — 4 indexed compounds with therapeutic class and molecular targets from public FDA and regional approval metadata.
Drug portfolio
-
-
US regulatory status: approved. Molecular target: DNA polymerase catalytic subunit.
- Target
- DNA polymerase catalytic subunit
- Mechanism
- Human herpesvirus 1 DNA polymerase inhibitor
-
Development asset linked to Candel Therapeutics in public FDA and regional records.
-
Development asset linked to Candel Therapeutics in public FDA and regional records.